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gate potential en(in)vironmental factors. As environmental 
conditions, in contrast to genetic risk factors, can be influ-
enced, knowledge on those risk factors becomes crucial to 
modulate disease incidence, disease course or clinical pre-
sentation. It is obvious that prevention of environmentally 
triggered disease flares would be a goal most relevant for 
IBD patients. An increased prevalence of IBD in urban envi-
ronment has been documented in Switzerland by the Swiss 
IBD cohort study. Several studies have attempted to identify 
such factors; however, only a few have been validated. The 
best investigated environmental factor identified in IBD co-
hort analyses is smoking. Other environmental factors that 
have been associated with clinical presentation or risk of in-
flammatory flares as well as increased incidence are diet and 
food additives. The so-called ‘hygiene hypothesis’ suggests 
that increased hygiene in childhood associated with re-
duced exposure to pathogens may leave the mucosal im-
mune system insufficiently trained and thus prone to uncon-
trolled inflammation. Oral contraceptives and non-steroidal 
anti-inflammatory drugs are the 2 main classes of frequently 
taken drugs that have been attributed to have the potential 
to cause flares of the disease. What is likely to be the connec-
tion between the genetic susceptibility and the environ-
mental triggers? There is broad evidence for a critical role of 
the commensal enteric microbiota as a modulator of immu-
nologic responses relevant during onset and chronification 
of IBD.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Inflammatory bowel disease (IBD) has become a ‘prototype 
disease’ for chronic auto-inflammatory disorders with a 
polygenic background and important multifaceted environ-
mental trigger components. The environmental factors con-
tribute both to pathogenesis and disease flares. Thus, IBD is 
a disease par excellence to study the interactions between 
host genetics, environmental factors (such as infections or 
smoking) and ‘in-vironmental’ factors – for example, our in-
testinal microbiota. Longitudinal intercurrent events, in-
cluding the impact of long-term medication on disease pro-
gression or stabilization, can exemplarily be studied in this 
disease group. Whilst alterations in the human genome cod-
ing relevant variant protein products have most likely not 
emerged significantly over the last 50 years, the incidence of 
Crohn’s disease and ulcerative colitis has dramatically in-
creased in Western countries and more recently in the Asia 
Pacific area. An interesting concept indicates that ‘Western 
lifestyle factors’ trigger chronic intestinal inflammation or 
disease flares in a genetically susceptible host. To under-
stand the disease pathogenesis as well as triggers for flares 
or determinants of disease courses, we must further investi-
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 Introduction 
 Inflammatory bowel disease (IBD) has become a pro-
totype for a polygenetic disease that is associated with 
many genetic risk factors  [1, 2] . For both ulcerative colitis 
(UC) and Crohn’s disease (CD), in the meantime, more 
than 200 single nucleotide polymorphisms have been 
identified in large genome-wide association studies  [3–8] .
 However, it is also clear that those genetic risk factors 
only partially contribute to the pathogenesis of IBD. 
Those ‘genetic risk factors’ are prevalent in our popula-
tion since hundreds of years. Nevertheless, in Europe and 
the United States, the so-called westernized countries, the 
incidence and prevalence of IBD has increased in the last 
100 years  [9, 10] . More recently, both incidence and prev-
alence of not only UC but also IBD in general have in-
creased in Asian countries such as China, Indonesia or 
India  [11] . In addition to that, forecasts suggest that IBD 
is continuously on the rise in the next few years, especial-
ly within the developing world  [12] . The recent increase 
in incidence clearly indicates that there must be environ-
mental factors that contribute to the onset of IBD.
 Most likely those causative environmental factors in 
IBD are associated with the changes of lifestyle and envi-
ronmental conditions that could be observed during the 
last 100 years in Europe and the last 20–30 years in many 
Asian countries. This has led to the concept that the onset 
of IBD is associated with specific factors of the so-called 
westernized lifestyle. The findings have also contributed 
to the ‘hygiene hypothesis’ suggesting that the improve-
ment in hygienic conditions and the reduction of so-
called natural stimulation of the intestinal immune sys-
tem are predisposing factors for the development of IBD 
 [13–16] . Obviously, people living under worse hygienic 
conditions have a lower risk to develop IBD. Of course, 
one of the major obstacles in the search of predictive en-
vironmental factors is that it is very hard to identify a 
single factor that has changed during the last 100 years  [1, 
17] . Hygienic improvement is always associated with 
changes in household equipment such as refrigerators or 
change in environmental bacteria.
 The Role of the Exposome: Onset of Disease or 
Disease Flares 
 It is now assumed that lifestyle and environmental fac-
tors in industrialized countries contribute up to 70% of 
the risk to develop IBD, whereas the genetic susceptibil-
ity is only responsible for about 30% of the disease inci-
dence  [1, 18–25] . On the other hand, it might well be that 
those environmental factors can mainly exert their influ-
ence in patients that have a certain genetic risk.
 The environmental factors that might be causative for 
any disease are now summarized under the term ‘expo-
some’ ( fig. 1 )  [1, 17, 26–30] . ‘Exposome’ refers to an um-
brella term, subsuming all the factors an individual is ex-
posed to during lifetime. Of course, the genetic suscepti-
bility is not changed in an individual during the action of 
an exposome. However, the exposome and the ‘infectome’ 
as a part of the exposome (representing the potential 
pathogens in the environment)  [31, 32] may either act on 
the microbiota composition of the gut or on the epigenetic 
imprinting of the cells of the intestinal mucosa  [1] .
 It is very hard to identify causative exposomal factors 
as they permanently influence an individual long before 
the onset of a disease. In the case of a patient with CD who 
develops first symptoms at the age of 18 years, we have to 
assume that the exposome continuously influenced this 
person for the last 18 years ( fig. 1 ). The specific hit that 
may have finally caused the onset of CD must not neces-
sarily have occurred right before the first symptoms have 
appeared. There might be a subclinical inflammation of 
the intestinal mucosa that only becomes apparent when 
some destruction of the bowel wall has already happened 
 [1] . In addition, there might be a histological inflamma-
tion even when no endoscopic inflammation is visible.
 As there is a long period of time when exposomal fac-
tors act on an individual without visible consequence, it 
appears to be almost impossible to identify specific envi-
ronmental factors that have a specific influence on onset 
of disease  [1] . For obvious reasons it is much easier to 
identify exposomal and environmental factors that in-
duce flares of UC or CD. Patients that suffer from IBD 
have already been identified and are closely followed up 
(e.g., in specific cohort projects such as the Swiss IBD Co-
hort Study, SIBDCS)  [33] . In such cohort projects, spe-
cific triggers of flares can be identified. Environmental 
triggers of flares also might play a role for the onset of the 
disease and the basic pathophysiology of disease develop-
ment. However, in those cases, the pathomechanisms be-
hind those factors need to be elucidated and subsequent-
ly proven in basic research approaches.
 Environmental Factors Known to Play a Role for 
Disease Flares 
 A number of factors have been identified that contribute 
to the risk of having a disease flare in a certain time period.
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 • Among the risk factors for disease flares, in both CD 
and UC, are low vitamin D levels  [34–39] . Surprising-
ly there is also an increased risk of vitamin D deficien-
cy in UC  [35, 37, 38, 40] . In patients with UC, the ab-
sorption of vitamin D should not be impaired as the 
inflammation only affects the large bowel. Neverthe-
less, the risk of a vitamin D deficiency is increased. In 
patients with vitamin D deficiency, in both CD and 
UC, the risk of having a flare is about 2-fold increased 
 [41] , whereas substitution in CD was shown to reduce 
relapse risk in quiescent CD  [42] . Moreover, lower vi-
tamin D serum levels were also revealed to be associ-
ated with an increased risk of colorectal cancer in IBD 
patients  [43] . 
 • There is still some controversy about non-steroidal an-
ti-rheumatic drugs (NSARs)  [44] . However, the re-
ports that indicate an increased risk of having a flare of 
CD and UC upon treatment with NSARs are more 
consistent  [45] . Overall risk (OR) between 1.6 and 1.9 
is reported in a recent review  [46, 47] . 
 • Many investigations have focused on the impact of 
diet on a disease course in IBD  [48–58] . Most con-
sistently, it has been shown that a high intake of po-
ly-unsaturated fatty acids as well as saturated fats, 
omega6 fatty acids and meat may increase the risk 
of having flares of CD or a more severe disease 
course. 
 • Whereas fibers and high fiber intake seem to be some-
what protective during remission and prevent flares of 
the disease  [59] . During the presence of a disease flare, 
the intake of fibers is not beneficial  [60] . 
 • Interestingly, oral contraceptives in women increase 
the risk of having a flare of CD to more than 2 fold  [18, 
61–66] . The same is true for hormone substitution 
therapy in UC  [18, 61–66] . Both factors indicate that 
hormonal influences also may play a role at least for 
the risk of disease flares. 
 • For breastfeeding, conflicting results have been report-
ed  [20, 67–71] . A meta-analysis could not conclusively 
decide whether there is a protective or even disease-
aggravating effect  [72] . If there is a protective effect at 
all it may be related to the duration of breastfeeding 
 [73] . 
 • Perhaps the best epidemiological evidence of a risk-
modifying property of an environmental factor is 
available for cigarette smoking  [74–77] . Cigarette 
smoking definitely is a risk factor for flares of CD and 
for perianal complications  [78–81] . Smoking has a 
clear negative effect on the disease course  [78–81] . On 
the other hand, smoking is protective and prevents 
flares in UC  [78, 82] . The mechanisms behind that are 
unclear. However, our group could show that smoking 
sensation clearly changes the composition of the intes-
tinal microbiota  [74, 83] . The change in microbiota 
 Fig. 1. Environmental factors (exposome, 
infectome and microbiota) that influence 
IBD onset and the risk of flares (modified 
according to  [1] ). The genetic susceptibility 
of a human remains constant during life-
time. In contrast, the exposome (blue ar-
row), the infectome – as part of the expo-
some – (grey arrow) and the microbiome 
(yellow arrow) permanently influence the 
function of the cells of the intestinal wall 
inducing epigenetic changes in those cells 
long before the onset of IBD. The expo-
some/infectome may either directly (blue 
arrow) cause epigenetic changes in an indi-
vidual of via influences transmitted by mi-
crobiota changes (grey and yellow arrows). 
Certain exposomal/environmental factors 
may then trigger the onset of IBD (red ar-
row). Their identification remains a major 
challenge. It is easier to identify environ-
mental factors (green) or microbiota fac-
tors (brown) that trigger disease flares. Ide-
ally, those factors can be avoided leading to 
controlled disease. 
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composition reveals a more pro-inflammatory profile. 
Those data indicate that smoking could indeed influ-
ence colitis risk via an important influence on the com-
position of the intestinal bacteria. 
 • The quality of life of patients with IBD is improved and 
stress is reduced in patients with CD who engage in 
regular low intensive exercise  [84, 85] . On the other 
hand, a long-term exercise with oxygen depletion may 
be deleterious and have contrary effects. Runner’s coli-
tis may not only be related to patients without IBD. 
This is indeed a risk for flares in patients with IBD. 
 • It is well known that anxiety and depressive symptoms 
also increase the risk of having a flare in the next 
12 months  [86, 87] . This has been nicely shown for CD 
 [46] . Other authors indicate that the same is true for 
UC  [88] . Also in the SIBDCS, anxiety was shown to be 
a relevant risk factor for disease flares  [89] . 
 • Hormonal replacement therapy may be a protective 
factor for postmenopausal female IBD patients  [90] . 
 • In a case–control study in pediatric patients, it has 
been shown that the presence of autoimmune diseases 
in the family is also a risk factor to develop IBD. 
 • Further protective factors were the number of siblings, 
the presence of pets and the present of a parasitosis in 
the family, all supporting the hygiene hypothesis. 
 Identification of Pathomechanisms 
 As mentioned above, in the case of environmental fac-
tors that can cause flares or may be responsible for onset of 
disease, the pathomechanisms have to be elucidated as a 
prerequisite to ultimately derive beneficial clinical impact 
for our patients. In a recent publication, we could identify 
a potential mechanism by which diet-derived nanoparti-
cles can induce inflammasome activation and therefore 
contribute to intestinal inflammation  [91] . One of those 
nanoparticles frequently used in the food industry is tita-
nium dioxide, usually used as microparticles. However, in 
industrially produced microparticles, about 10% of the 
particles appear to be nanoparticles of about 100 nm of size. 
Those particles can penetrate cell membranes by physical 
interaction without needing a receptor. The total uptake of 
nanoparticles by patients is at an average of 2.5 mg per per-
son and day but may increase up to 40 mg. Interestingly, 
there is a high content of titanium dioxide in coffee whit-
ener, pastry (due to the flour content), toothpaste, chewing 
gum or drug preparations. We could demonstrate that ti-
tanium dioxide activates the immune system  [91] . This ac-
tivation is mainly mediated via a protein complex called 
the inflammasome. The inflammasome consists of 3 sub-
units. The effector subunit is caspase-1 that cleaves pro-
interleukin 1β (IL-1β) and to the mature IL-1β and pro-
IL-18 that can then be secreted. We found that in cell cul-
ture titanium dioxide was a strong activator of the 
inflammasome and subsequently induced IL-1β release 
 [91] . In a mouse model, there was an aggravation of colitis 
induced by dextran sodium sulfate in the presence of tita-
nium dioxide in the diet  [91] . This effect was concentration 
dependent. In NALP3, this effect was absent in knockout 
mice that lack the receptor for inorganic nanoparticles 
 [91] . Interestingly, in patients with active UC, we could 
measure increased titanium levels in the blood serum indi-
cating that indeed in patients with active inflammation of 
the colon titanium dioxide is taken up into the body  [91] . 
When it is taken up, it most likely also activates the inflam-
masome; however, we have not proven that directly in our 
manuscript. Similarly, other food additives may activate 
the immune system. Among those food additives may be 
aluminum as shown by Pineton de Chambrun et al.  [92] .
 Another recently highlighted compound that is fre-
quently used in the food industry is emulgators. A recent 
highly appreciated manuscript has shown that emulga-
tors may aggravate colitis by probably reducing the mu-
cus layer in the colon, which would then be a mechanism 
that impairs the barrier function of the intestine  [93] .
 Microbiota, Antibiotics and IBD 
 There are a number of epidemiological studies that show 
that antibiotics may increase the risk of IBD. Hviid et al.  [94] 
have shown in a Dutch registry that antibiotic use in child-
hood increases the risk of IBD. Especially the tetracycline 
class of antibiotics and particularly doxycycline use was 
shown by his group to be associated with the development 
of IBD, particularly CD  [94] . A similar association for oral 
tetracycline use and IBD has been identified by Margolis et 
al.  [95] . Bernstein et al.  [96–99] in Canada also could dem-
onstrate that there is an association between the use of an-
tibiotics in the first year of life and pediatric IBD. By the 
same group, an association between the use of antibiotics 
and new diagnosis of CD and UC in the adult population 
was shown. The antibiotics usually had been prescribed 
2–5 years before the diagnosis. A recent meta-analysis by 
Ungaro et al.  [100] in Am J Gastroenterology summarized 
12 studies that focused on the risk of having IBD after the 
use of antibiotics. The meta-analysis indicates an OR of 1.57 
with high statistical significance indicating that indeed an-
tibiotic use may later on cause IBD  [100] .
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 However, as always those results have to been inter-
preted with caution. We have all learned that IBD is as-
sociated with a defect in innate immunity and such a de-
fect may also manifest in increased number of infections. 
Those infections then would request antibiotic treatment. 
So the increased use of antibiotics in patients who finally 
suffer from IBD may just indicate an increase in the pre-
disposition to infections due to the impaired innate im-
munity. This would mean that antibiotic use is just a fac-
tor associated with IBD but not at all causative or patho-
physiologically relevant. Likewise, it appears perfectly 
plausible, that antibiotic usage in childhood reflects a 
proxy for a general ‘higher’ living standard, as children 
associated to a higher social stratum may grow up in a 
‘high-hygiene environment’, accompanied by a lower 
threshold for visits to a physician and thus higher expo-
sure to antibiotics.
 Antibiotics have been shown to cause a dysbiosis  [101–
103] . Similar dysbiosis has been found in many patients 
with IBD. However, this may not necessarily be negative. 
Metronidazole, which has some beneficial effects during 
acute phases of UC and also in patients with CD who suf-
fer from fistulae, clearly reduces the diversity upon treat-
ment as we have shown recently (unpublished data). Ac-
cordingly, simultaneously with reducing the microbial 
diversity, it exerts beneficial effects for IBD patients. This 
indicates that a reduction of diversity of the microflora 
may not always be a negative effect. We have to learn a lot 
more about the impact of the microbiota on the intestinal 
immune system before we are able to draw any conclu-
sions.
 Other Environmental Factors 
 A recent factor we recently identified within the Swiss 
IBD Cohort to potentially contribute to the risk of having 
flares of IBD is high altitude journeys of flights  [104, 105] . 
In the population we studied, there was a significant as-
sociation of high altitude journeys and flights with the 
risk of having a flare of IBD  [104, 105] . The days spent on 
altitudes above 2,000 m were also associated with the risk 
of having a disease flare. The same was true for the dis-
tance of the airplane flights. Whereas short distance 
flights seem to have a lower risk, the risk associated with 
long-term flights was higher.
 Another risk factor for IBD flares we recently identi-
fied in the SIBDCS is the presence of heat waves, which 
clearly revealed to induce IBD flares  [106] . With a latency 
period, they also induced bacterial or viral gastroenteritis. 
However, as the flares of IBD appeared with less latency 
as compared to the gastroenteritis, it is highly unlikely 
that an antecedent infection reflected the actual trigger 
the flare of IBD. Obviously, there must be a pathogenetic 
mechanism by which the physiological stress course by a 
heat wave directly may trigger a flare of IBD  [106] .
 Summary 
 As environmental changes that trigger disease flares or 
the onset of CD and UC are of utmost importance for our 
patients, we have to learn more about underlying mecha-
nisms, for example, whether hypoxia is protective or 
causes flares of IBD. Situations of hypoxia can be avoided 
or can be prevented as many of the environmental factors.
 Environmental factors and lifestyle factors, the so-
called exposome, most likely contribute significantly to 
onset and disease course of IBD. Results from epidemi-
ological studies for many of the lifestyle factors such as 
diet or breastfeeding are conflicting. One of the reasons 
for those conflicting data is the fact, that we frequently 
do not understand the underlying pathophysiological 
mechanisms, but instead just observe associations of 
those environmental factors with an increase in disease 
risk. Evidently, association is not equal to causality. 
Confounders may bias many of those studies, as for in-
stance eluted to regarding antibiotics. Therefore, we are 
faced with a largely unmet need to identify the patho-
physiological pathways at present that genuinely con-
tribute to the impact of environmental factors on disease 
course.
 Non-classical lifestyle factors such as hypoxia, travel-
ling and climate may play an important role that has to be 
further investigated. The effects of those factors may ei-
ther be mediated by the intestinal microbiota or directly 
via the innate immune system in epithelial cells or the 
mucosal immune system.
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